• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>Barr Pharmaceuticals

Barr Pharmaceuticals

  1. All
  2. Morningstar Articles
  3. Investing
  1. What Maslow and Rand Would Tell Investors Today

    We're placing Barr Pharmaceuticals BRL under review while we evaluate the company's decision, announced Tuesday, to acquire Pliva. Barr is paying $2.2 billion in cash for the Croatia-based generic drug firm. The transaction geographically diversifies Barr's primarily U.S.-based operations, as 78% ...

  2. Stockton is Bankrupt: Now What?

    Plus, a top executive bolts from eBay, Brazilian telcos get cheap, and more.

  3. Nick Kaiser, Saturna Capital

    Nick Kaiser's Amana funds, which invest according to Islamic law, are trouncing their large-cap competition.

Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.